- 11 May | Right Approach to Study Economy For Beginners Click Here →
- 05 May | Caution!! You may enter into No productivity Zone Click Here →
- 07 May | How Toppers identify the Implicit Demand of the Question Click Here to watch Ujjawal Priyank IAS AIR 10 Strategy →
Contents
Source: The post is based on the article “Explained | Will new drug slow the progress of Alzheimer’s?” published in The Hindu on 12th December 2022
What is the News?
Recently, detailed results from a clinical trial involving Lecanemab drug for Alzheimer’s disease were published.
The findings indicate the drug was effective in slowing cognitive decline for some patients with Alzheimer’s disease potentially representing the first significant treatment advance in decades.
What is Lecanemab?
Lecanemab is a drug that is currently in clinical trials for the treatment of Alzheimer’s disease.
Developed by: Pharma companies Biogen and Eisai.
Type: Lecanemab belongs to a class of drugs called monoclonal antibodies. These antibody-mediated drugs target beta-amyloid, the protein deposition that is seen in patients with Alzheimer’s disease and disrupts cell function.
